ClinicalTrials.gg
CompletedNCT04185246Updated Nov 18, 2025Results posted

A Dose Ascending Study to Evaluate the Safety of NH002 as a Contrast Agent in Cardiac Echocardiography

A Phase 1/2 interventional study of NH002 (Perflutren Lipid Microspheres) Injectable Suspension and Echocardiogram in Cardiac Disease, sponsored by Trust Bio-sonics, Inc.. Completed at 2 sites in Taiwan. Open to participants aged 20 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-11-18.

Sponsored by Trust Bio-sonics, Inc. · Phase 1/2, Interventional, and Diagnostic

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
36
Allocation
Not applicable
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 25 studies in Heart Diseases with a site in Taiwan — 4 open to participants now, 7 under way, 3 of them phase 3. Heart Diseases · Taiwan.

Enrollment
21st of 22
36 · median 556
Started
2019
the only one that year
Phase 1/2
Only one
of the 25
Registered
13th of 25
by date
Lead sponsor
2 of 25
Trust Bio-sonics, Inc.

Among the 25 studies in Heart Diseases with a site in Taiwan, this one is the 21st largest by enrollment of the 22 interventional ones that give a count, is the only one that started in 2019, is the only one in phase 1/2, and was the 13th registered.

Heart Diseases

2,135 studies on the registry are indexed under Heart Diseases; 252 are open to participants now.

Browse Heart Diseases studies →

Open to participants now

4 of the 25 studies in Heart Diseases with a site in Taiwan are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →

Who these studies take

Of the 181 Heart Diseases studies recruiting now, 128 (71%) set no upper age limit and 21 (12%) stop at 75 or younger; 32 take children under 18; 42 take healthy volunteers.

This study: 20 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies in Heart Diseases with a site in Taiwan, or all of them as a file.
02

Study summary

NH002 (Perflutren Lipid Microspheres) Injectable Suspension is an ultrasound contrast agent for use in patients with suboptimal echocardiograms to opacify the left ventricular (LV) chamber and to improve the delineation of the LV endocardial border. The primary objective of this study is to evaluate the safety and tolerability of 3 ascending doses of NH002.

03

Conditions studied

  • Cardiac Disease

Browse trials for

Keywords

  • Echo
  • Echocardiogram
  • Cardiac ultrasound
  • suboptimal
  • contrast agent
  • enhancing agent
  • LVO
  • LVEBD
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female subjects 20 years of age or older
  2. Ability to understand and the willingness to provide written
  3. Suspected of having cardiac disease or undergoing evaluation of cardiac anatomy for congenital heart disease
  4. Negative pregnancy test within 24 hours of the procedure if subject is a woman of

Exclusion criteria

Exclusion Criteria:

  1. Known right-to-left, bidirectional, or transient right-to-left cardiac shunt(s)
  2. at screening or baseline \<40%
  3. Uncontrolled serious ventricular arrhythmias or at high risk for arrhythmias due to prolongation of the (QT corrected by Fridericia's formula >450 msec in males and >470 msec in females)
  4. abnormality in renal and liver function tests (/aspartate aminotransferase >2 × [ULN]; serum creatinine > 1.5 × ULN)
  5. Known or suspected to one or more of the ingredients of NH002, perflutren, or other echocardiographic contrast agent
  6. Received an compound within 30 days before enrolling in the study
  7. Received any contrast agent either intravascularly or orally within 48 hours before NH002 administration
  8. Pregnant or lactating female (conception during the study should be avoided)
  9. Serious medical or psychiatric illness/condition likely, in the judgment of the investigator, to interfere with compliance to protocol treatment/research
  10. Clinically unstable cardiopulmonary conditions considered not suitable for participation in the trial, in the judgment of the investigator
  11. Uncontrolled arterial hypertension (defined as systolic blood pressure ≥ 200 mmHg or diastolic blood pressure ≥ 110 mmHg) or arterial hypotension (defined as systolic blood pressure ≤ 90 mmHg)
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
36 participants (actual)

Study arms

  • Experimental
    Single arm

    Subjects will be enrolled with sequential allocation to 1 of 3 cohorts with the following intravenous (IV) doses of NH002: 2.5 µl/kg, 5.0 µl/kg, or 10.0 µl/kg. Each patient will undergo an unenhanced ultrasound examination and a NH002 contrast-enhanced examination on the same day

    Drug: NH002 (Perflutren Lipid Microspheres) Injectable Suspension · Diagnostic Test: Echocardiogram

Interventions

  • NH002 is formulated as a microbubble injectable suspension for intravenous administration. NH002 requires an activation process prior to use.

  • Diagnostic testEchocardiogram

    Each patient will undergo an unenhanced ultrasound examination and a NH002 contrast-enhanced examination on the same day.

06

What researchers measure

Primary outcomes

  1. 12-lead ECGs

    Standard 12-lead ECGs will be assessed from pre-injection to 60 minutes post-injection for changes in QT/ corrected QT(QTc) interval (in ms) and ECG morphology; each standard 12-lead ECG assessment will be scored as either normal or abnormal

    Time frame: From pre-injection to 60 minutes post injection

  2. Body Temperature

    Monitor for any changes in body temperature (in Celsius degree)

    Time frame: From pre-injection to 120 minutes post injection

  3. Heart Rate

    Monitor for any changes in heart rate (in beats/min)

    Time frame: From pre-injection to 120 minutes post injection

  4. Respiratory Rate

    Monitor for any changes in respiratory rate (in breaths/min)

    Time frame: From pre-injection to 120 minutes post injection

  5. Blood Pressure

    Monitor for any changes in blood pressure (in mmHg)

    Time frame: From pre-injection to 120 minutes post injection

  6. Thrombin Time (TT) and Activated Partial Thromboplastin Time (aPTT)

    Monitor for any changes in TT and aPTT

    Time frame: From pre-injection to 240 minutes post-injection

  7. Cardiac Troponin I

    Monitor for any changes in Cardiac troponin I

    Time frame: pre-injection and 240 minutes post-injection

  8. Oxygen Saturation by Pulse Oximetry (SpO2)

    Monitor for any changes in SpO2

    Time frame: From pre-injection to 120 minutes post-injection

  9. Rate of Any Potential Adverse Allergic Reaction

    Monitor for any potential adverse allergic reaction

    Time frame: From pre-injection to 240 minutes post-injection

  10. Cardiac Troponin T

    Monitor for any changes in Cardiac troponin T

    Time frame: pre-injection and 240 minutes post-injection

Secondary outcomes

  1. Left Ventricular Opacification (LVO)

    The percentage of subjects with moderate or complete left ventricular opacification (LVO), defined by an LVO grade of 2 (moderate) or 3 (complete), as assessed by the blinded central reader(s). The percentage of subjects with complete LVO, defined by an LVO grade of 3 (complete), as assessed by the blinded central reader(s)

    Time frame: Image data obtained pre-injection and within 10 minutes post-injection

  2. Left Ventricular Endocardial Border Delineation (LVEBD)

    The change from baseline on the left ventricular endocardial border delineation (LVEBD) score, defined using a standard 12-segment model, as assessed by the blinded central reader(s). The left ventricular (LV) endocardium of the 4- or 2- chamber apical views are divided into 6 segments, with 2 basal, mid- and apical segments in each view. For each segment, LVEBD is graded as follows: 0= inadequate border (border not visible); 1= sufficient (border barely visible); 2= good (border clearly visible). A total delineation score (0-24) is obtained by adding the scores from the 6 individual segments in each of the 2 views. The changes from baseline on LVEBD score of subjects with suboptimal LVEBD at baseline, as defined by 2 or more contiguous segments of 6 segments that cannot be visualized reliably in either the apical 4 and/or the 2-chamber view, as assessed by the blinded central reader(s)

    Time frame: Image data obtained pre-injection and within 10 minutes post-injection

  3. Duration of Clinically Useful Contrast

    A duration of clinically useful contrast calculated by measuring the time between the disappearance of shadowing effect (useful effect starts) and the time when moderate or full LV enhancement and contrast enhancement are no longer adequate (useful effect ends), as assessed by the blinded central reader(s)

    Time frame: Image data obtained pre-injection and within 10 minutes post-injection

07

Results

Posted Dec 20, 2024

Participant flow

Participant flow — Overall Study
MilestoneCohort 1Cohort 2Cohort 3
Started121212
Completed121212
Not completed000

Outcome measures

Primary12-lead ECGs

Standard 12-lead ECGs will be assessed from pre-injection to 60 minutes post-injection for changes in QT/ corrected QT(QTc) interval (in ms) and ECG morphology; each standard 12-lead ECG assessment will be scored as either normal or abnormal

Time frame:
From pre-injection to 60 minutes post injection
Reported as:
Mean · millisecond
12-lead ECGs
millisecondCohort 1Cohort 2Cohort 3
Baseline (QT)393.9 ± 19.37392.0 ± 24.07386.3 ± 25.99
Change of Baseline (QT) at 10 minutes post-dose2.8 ± 13.65-6.0 ± 13.166.8 ± 17.65
Change of Baseline (QT) at 30 minutes post-dose10.8 ± 13.286.0 ± 12.5916.0 ± 13.4
Change of Baseline (QT) at 60 minutes post-dose7.1 ± 17.173.4 ± 17.1710.6 ± 9.59
Baseline (QTc)415.1 ± 21.71415.9 ± 20.38404.6 ± 15.32
Change of baseline (QTc) at 10 minutes post-dose1.3 ± 13.92-6.4 ± 10.957.8 ± 7.7
Change of baseline (QTc) at 30 minutes post-dose0.4 ± 14.25-1.3 ± 12.148.8 ± 9.17
Change of baseline (QTc) at 60 minutes post-dose-0.1 ± 13.03-3.0 ± 11.966.9 ± 5.88
PrimaryBody Temperature

Monitor for any changes in body temperature (in Celsius degree)

Time frame:
From pre-injection to 120 minutes post injection
Reported as:
Mean · Celsius degree
Body Temperature
Celsius degreeCohort 1Cohort 2Cohort 3
Baseline36.76 ± 0.29436.73 ± 0.30636.76 ± 0.385
Change from baseline at 5 minutes post-dose-0.01 ± 0.215-0.02 ± 0.195-0.01 ± 0.268
Change from baseline at 10 minutes post-dose-0.01 ± 0.3120.07 ± 0.235-0.06 ± 0.207
Change from baseline at 30 minutes post-dose-0.07 ± 0.3280.11 ± 0.2150 ± 0.2
Change from baseline at 60 minutes post-dose-0.08 ± 0.4570.05 ± 0.271-0.18 ± 0.313
Change from baseline at 120 minutes post-dose-0.07 ± 0.4420.1 ± 0.283-0.02 ± 0.518
PrimaryHeart Rate

Monitor for any changes in heart rate (in beats/min)

Time frame:
From pre-injection to 120 minutes post injection
Reported as:
Mean · beats/minute
Heart Rate
beats/minuteCohort 1Cohort 2Cohort 3
Baseline70.1 ± 9.9371.3 ± 7.7369.0 ± 8.06
Change from baseline at 10 minutes post-dose-0.7 ± 2.71-0.1 ± 5.87-0.1 ± 3.73
Change from baseline at 30 minutes post-dose-3.0 ± 5.34-1.3 ± 5.99-0.3 ± 6.85
Change from baseline at 60 minutes post-dose-0.9 ± 5.96-1.2 ± 4.370.7 ± 4.56
Change from baseline at 120 minutes post-dose4.9 ± 10.296.8 ± 12.48.3 ± 9.9
PrimaryRespiratory Rate

Monitor for any changes in respiratory rate (in breaths/min)

Time frame:
From pre-injection to 120 minutes post injection
Reported as:
Mean · breaths/minute
Respiratory Rate
breaths/minuteCohort 1Cohort 2Cohort 3
Baseline15.6 ± 3.5515.1 ± 2.0716.9 ± 4.44
Change from baseline at 10 minutes post-dose0.6 ± 3.8-0.6 ± 3.29-1.4 ± 3.12
Change from baseline at 30 minutes post-dose0.9 ± 3.09-0.8 ± 3.28-1.3 ± 4.71
Change from baseline at 60 minutes post-dose0.5 ± 3.85-0.9 ± 2.75-2.3 ± 4.09
Change from baseline at 120 minutes post-dose0.8 ± 3.43-0.5 ± 3.61-1.3 ± 4.48
PrimaryBlood Pressure

Monitor for any changes in blood pressure (in mmHg)

Time frame:
From pre-injection to 120 minutes post injection
Reported as:
Mean · mmHg
Blood Pressure
mmHgCohort 1Cohort 2Cohort 3
Baseline (SBP)132.8 ± 14.93106.8 ± 15.6112.7 ± 16.33
Change from baseline (SBP) at 10 minutes post-dose-2.5 ± 9.480.5 ± 6.45-0.3 ± 7.76
Change from baseline (SBP) at 30 minutes post-dose-5.2 ± 11.544.8 ± 13.334.1 ± 9.46
Change from baseline (SBP) at 60 minutes post-dose-4.8 ± 15.031.5 ± 12.596.0 ± 10.44
Change from baseline (SBP) at 120 minutes post-dose-4.0 ± 13.17.6 ± 15.4713.8 ± 19.6
Baseline (DBP)85.2 ± 11.6168.5 ± 13.371.5 ± 11.76
Change from baseline (DBP) at 10 minutes post-dose-2.6 ± 6.560 ± 4.922.6 ± 5.96
Change from baseline (DBP) at 30 minutes post-dose-3.9 ± 8.124.1 ± 10.663.1 ± 9.6
Change from baseline (DBP) at 60 minutes post-dose-3.0 ± 10.43.6 ± 11.527.8 ± 11.58
Change from baseline (DBP) at 120 minutes post-dose-2.3 ± 7.946.8 ± 14.168.7 ± 14.5
PrimaryThrombin Time (TT) and Activated Partial Thromboplastin Time (aPTT)

Monitor for any changes in TT and aPTT

Time frame:
From pre-injection to 240 minutes post-injection
Reported as:
Mean · seconds
Thrombin Time (TT) and Activated Partial Thromboplastin Time (aPTT)
secondsCohort 1Cohort 2Cohort 3
Baseline (TT)18.6 ± 3.14517.81 ± 0.66716.7 ± 1.836
Change from baseline (TT) at 60 minutes post-dose0.22 ± 0.395-0.12 ± 0.387-0.24 ± 0.724
Change from baseline (TT) at 120 minutes post-dose0.06 ± 0.5280.05 ± 0.95-0.3 ± 0.662
Change from baseline (TT) at 240 minutes post-dose0.11 ± 0.497-0.05 ± 0.620.31 ± 1.274
Baseline (APTT)31.54 ± 3.88828.76 ± 27.8128.87 ± 2.796
Change from baseline (APTT) at 60 minutes post-dose-0.3 ± 2.625-1.05 ± 2.184-0.8 ± 2.921
Change from baseline (APTT) at 120 minutes post-dose-0.49 ± 3.11-0.48 ± 1.788-0.61 ± 2.586
Change from baseline (APTT) at 240 minutes post-dose-0.55 ± 3.191-0.68 ± 1.516-1.5 ± 2.375
PrimaryCardiac Troponin I

Monitor for any changes in Cardiac troponin I

Time frame:
pre-injection and 240 minutes post-injection
Reported as:
Mean · ng/mL
Cardiac Troponin I
ng/mLCohort 1Cohort 2Cohort 3
Baseline (troponin I)0.005 ± 0.0000.005 ± 0.0000.005 ± 0.000
240 minutes after dosing (troponin I)0.005 ± 0.0000.005 ± 0.0000.005 ± 0.000
Change from baseline (troponin I) at 240 minutes post-dose0.000 ± 0.0000.000 ± 0.0000.000 ± 0.000
PrimaryOxygen Saturation by Pulse Oximetry (SpO2)

Monitor for any changes in SpO2

Time frame:
From pre-injection to 120 minutes post-injection
Reported as:
Mean · percentage
Oxygen Saturation by Pulse Oximetry (SpO2)
percentageCohort 1Cohort 2Cohort 3
Baseline98.8 ± 1.0698.9 ± 1.5198.3 ± 1.14
Change from baseline at 10 minutes post-dose0.4 ± 1.310.3 ± 0.62-0.4 ± 1.38
Change from baseline at 30 minutes post-dose0.2 ± 1.270.3 ± 1.29-0.3 ± 0.87
Change from baseline at 60 minutes post-dose0.5 ± 1.880.4 ± 1.380.8 ± 1.22
Change from baseline at 120 minutes post-dose0 ± 1.13-0.2 ± 1.640.2 ± 0.94
PrimaryRate of Any Potential Adverse Allergic Reaction

Monitor for any potential adverse allergic reaction

Time frame:
From pre-injection to 240 minutes post-injection
Reported as:
Count of participants · Participants
Rate of Any Potential Adverse Allergic Reaction
ParticipantsCohort 1Cohort 2Cohort 3
Rate of Any Potential Adverse Allergic Reaction000
SecondaryLeft Ventricular Opacification (LVO)

The percentage of subjects with moderate or complete left ventricular opacification (LVO), defined by an LVO grade of 2 (moderate) or 3 (complete), as assessed by the blinded central reader(s). The percentage of subjects with complete LVO, defined by an LVO grade of 3 (complete), as assessed by the blinded central reader(s)

Time frame:
Image data obtained pre-injection and within 10 minutes post-injection
Reported as:
Count of participants · Participants
Left Ventricular Opacification (LVO)
ParticipantsCohort 1Cohort 2Cohort 3
LVO grade of 2 (moderate) or 3 (complete)121212
LVO grade of 3 (complete)111212
SecondaryLeft Ventricular Endocardial Border Delineation (LVEBD)

The change from baseline on the left ventricular endocardial border delineation (LVEBD) score, defined using a standard 12-segment model, as assessed by the blinded central reader(s). The left ventricular (LV) endocardium of the 4- or 2- chamber apical views are divided into 6 segments, with 2 basal, mid- and apical segments in each view. For each segment, LVEBD is graded as follows: 0= inadequate border (border not visible); 1= sufficient (border barely visible); 2= good (border clearly visible). A total delineation score (0-24) is obtained by adding the scores from the 6 individual segments in each of the 2 views. The changes from baseline on LVEBD score of subjects with suboptimal LVEBD at baseline, as defined by 2 or more contiguous segments of 6 segments that cannot be visualized reliably in either the apical 4 and/or the 2-chamber view, as assessed by the blinded central reader(s)

Time frame:
Image data obtained pre-injection and within 10 minutes post-injection
Reported as:
Mean · score on a scale
Left Ventricular Endocardial Border Delineation (LVEBD)
score on a scaleCohort 1Cohort 2Cohort 3
LVEBD scores_Baseline (all subjects)11.5 ± 6.758.9 ± 4.899.7 ± 6.68
LVEBD scores_Post-dose (all subjects)23.0 ± 3.4623.8 ± 0.6223.9 ± 0.29
Change from baseline (all subjects)11.5 ± 7.2214.8 ± 4.7114.3 ± 6.59
LVEBD scores_Baseline (subjects with suboptimal LVEBD at baseline)8.6 ± 4.487.4 ± 3.727.8 ± 6.65
LVEBD scores_Post-dose (subjects with suboptimal LVEBD at baseline)22.7 ± 4.023.7 ± 0.6723.9 ± 0.33
Change from baseline (subjects with suboptimal LVEBD at baseline)14.1 ± 6.1116.3 ± 3.5616.1 ± 6.57
SecondaryDuration of Clinically Useful Contrast

A duration of clinically useful contrast calculated by measuring the time between the disappearance of shadowing effect (useful effect starts) and the time when moderate or full LV enhancement and contrast enhancement are no longer adequate (useful effect ends), as assessed by the blinded central reader(s)

Time frame:
Image data obtained pre-injection and within 10 minutes post-injection
Reported as:
Mean · minutes
Duration of Clinically Useful Contrast
minutesCohort 1Cohort 2Cohort 3
Duration of Clinically Useful Contrast7.2 ± 2.4587.67 ± 1.6843.59 ± 1.854
PrimaryCardiac Troponin T

Monitor for any changes in Cardiac troponin T

Time frame:
pre-injection and 240 minutes post-injection
Reported as:
Mean · ng/L
Cardiac Troponin T
ng/LCohort 1Cohort 2Cohort 3
Baseline (troponin T)4.07 ± 2.531.5 ± 0.04.38 ± 1.824
240 minutes after dosing (troponin T)5.21 ± 1.3682.3 ± 1.1055.72 ± 4.387
Change from baseline (troponin T) at 240 minutes post-dose1.14 ± 1.8780.8 ± 1.1051.34 ± 3.833

Adverse events

Collected over Each subject had to be carefully monitored for the development of any AEs throughout the study from the signing of the informed consent form to 7 days after receipt of the dose of study agent.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort 10/12 (0%)0/12 (0%)0/12 (0%)
Cohort 20/12 (0%)0/12 (0%)2/12 (16.7%)
Cohort 30/12 (0%)0/12 (0%)7/12 (58.3%)
Most frequent other events
Showing 10 of 13
Most frequent other events
EventCohort 1Cohort 2Cohort 3
DizzinessNervous system disorders0/120/123/12
Chest discomfortGeneral disorders0/120/122/12
DyspnoeaRespiratory, thoracic and mediastinal disorders0/121/122/12
FlushingVascular disorders0/120/122/12
PalpitationsCardiac disorders0/120/122/12
Ocular hyperaemiaEye disorders0/120/122/12
Chest painGeneral disorders0/121/121/12
ChillsGeneral disorders0/120/121/12
Head discomfortNervous system disorders0/120/121/12
HeadacheNervous system disorders0/120/121/12

Baseline characteristics

Age, Continuous
Age, Continuous(years)Cohort 1Cohort 2Cohort 3Total
Mean43.5 ± 14.7738.8 ± 10.2936.8 ± 11.4239.7 ± 12.29
Sex: Female, Male
Sex: Female, Male(Participants)Cohort 1Cohort 2Cohort 3Total
Female47617
Male85619
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Cohort 1Cohort 2Cohort 3Total
American Indian or Alaska Native0000
Asian12121236
Native Hawaiian or Other Pacific Islander0000
Black or African American0000
White0000
More than one race0000
Unknown or Not Reported0000
Height
Height(centimeter)Cohort 1Cohort 2Cohort 3Total
Mean168.4 ± 11.396163.7 ± 10.93166.74 ± 11.991166.28 ± 11.29
Weight
Weight(kilogram)Cohort 1Cohort 2Cohort 3Total
Mean76.88 ± 21.99263.17 ± 13.13173.59 ± 22.27971.21 ± 19.933
08

Study locations

2 sites
  • Taipei Mackay Memorial Hospital
    Taipei, 10449, Taiwan
  • Taipei Veterans General Hospital
    Taipei, 11217, Taiwan
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2019 to primary completion in Jul 2020, 7 months.

Results were first posted in Dec 2024, 4 years 5 months after primary completion. A results delay was requested in Jun 2021.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 6, 2019
First posted
Dec 4, 2019
StartActual
Nov 4, 2019
Primary completionActual
Jul 1, 2020
CompletionActual
Jul 1, 2020
Results delay requested
Jun 29, 2021
Results first posted
Dec 20, 2024
Last update
Nov 18, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 18, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04185246
Lead sponsor
Trust Bio-sonics, Inc.
Collaborators
StatPlus,Inc.
Responsible party
Sponsor
First posted
Dec 4, 2019
Start date
Nov 4, 2019
Primary completion
Jul 1, 2020
Completion
Jul 1, 2020
Results posted
Dec 20, 2024
Last update
Nov 18, 2025

Study contacts

Wen-Chung Yu
principal investigator · Taipei Veterans General Hospital, Taiwan
Chung-Lieh Hung
principal investigator · Taipei Mackay Memorial Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Perflutren

Start the discussion